AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 49 filers reported holding AUDENTES THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $24,534,000 | +113.0% | 410,000 | 0.0% | 0.78% | +68.8% |
| Q3 2019 | $11,517,000 | -25.8% | 410,000 | 0.0% | 0.46% | -18.3% |
| Q2 2019 | $15,523,000 | -23.9% | 410,000 | -21.5% | 0.56% | -28.5% |
| Q1 2019 | $20,388,000 | +91.3% | 522,500 | +4.5% | 0.79% | +56.3% |
| Q4 2018 | $10,660,000 | -36.6% | 500,000 | +17.6% | 0.50% | -17.4% |
| Q3 2018 | $16,827,000 | +0.1% | 425,025 | -3.4% | 0.61% | -5.9% |
| Q2 2018 | $16,812,000 | -1.0% | 440,000 | -22.1% | 0.65% | -10.6% |
| Q1 2018 | $16,978,000 | +3.5% | 565,000 | +7.6% | 0.72% | -2.7% |
| Q4 2017 | $16,406,000 | +11.6% | 525,000 | 0.0% | 0.74% | +9.7% |
| Q3 2017 | $14,705,000 | +29.1% | 525,000 | -11.8% | 0.68% | +17.9% |
| Q2 2017 | $11,386,000 | +33.6% | 595,200 | +19.0% | 0.58% | +16.9% |
| Q1 2017 | $8,520,000 | -3.8% | 500,000 | +3.1% | 0.49% | -17.0% |
| Q4 2016 | $8,861,000 | +2.6% | 485,000 | 0.0% | 0.59% | +9.6% |
| Q3 2016 | $8,638,000 | – | 485,000 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,204,615 | $37,644,219,000 | 39.61% |
| Casdin Capital, LLC | 400,000 | $12,500,000 | 3.04% |
| Opaleye Management Inc. | 210,000 | $6,652,000 | 2.13% |
| Orbimed Advisors | 4,129,638 | $129,051,000 | 1.63% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,190,516 | $37,204,000 | 1.46% |
| Redmile Group, LLC | 929,326 | $29,041,000 | 1.26% |
| Cormorant Asset Management, LP | 337,876 | $10,559,000 | 1.10% |
| Perceptive Advisors | 781,309 | $24,416,000 | 0.81% |
| Rock Springs Capital Management LP | 525,000 | $16,406,000 | 0.74% |
| Virtus ETF Advisers LLC | 11,898 | $372,000 | 0.47% |